| Primary |
| Multiple Sclerosis |
18.2% |
| Lymphoma |
14.5% |
| Acute Myeloid Leukaemia |
12.7% |
| Immunosuppression |
10.9% |
| Prophylaxis |
10.9% |
| Acute Promyelocytic Leukaemia |
7.3% |
| Secondary Progressive Multiple Sclerosis |
7.3% |
| Breast Cancer Metastatic |
3.6% |
| Product Used For Unknown Indication |
3.6% |
| Relapsing-remitting Multiple Sclerosis |
3.6% |
| Acute Myeloblastic Leukaemia |
1.8% |
| B-cell Lymphoma Stage Iv |
1.8% |
| Non-hodgkin's Lymphoma |
1.8% |
| Primary Progressive Multiple Sclerosis |
1.8% |
|
| Acute Promyelocytic Leukaemia |
24.2% |
| Acute Myeloid Leukaemia |
6.1% |
| Breast Cancer |
6.1% |
| Cardiomyopathy |
6.1% |
| Pneumonia |
6.1% |
| Tumour Lysis Syndrome |
6.1% |
| Weight Decreased |
6.1% |
| Acute Lymphocytic Leukaemia |
3.0% |
| Bone Marrow Transplant |
3.0% |
| Chronic Myelomonocytic Leukaemia |
3.0% |
| Colitis Ischaemic |
3.0% |
| Idiosyncratic Drug Reaction |
3.0% |
| Left Ventricular Dysfunction |
3.0% |
| Meningitis Herpes |
3.0% |
| Metastases To Liver |
3.0% |
| Neutropenic Sepsis |
3.0% |
| Oedema Peripheral |
3.0% |
| Pancytopenia |
3.0% |
| Pulmonary Alveolar Haemorrhage |
3.0% |
| Pyrexia |
3.0% |
|
| Secondary |
| Acute Myeloid Leukaemia |
17.9% |
| B-cell Lymphoma |
11.1% |
| Product Used For Unknown Indication |
10.2% |
| Non-hodgkin's Lymphoma |
8.8% |
| Neoplasm Malignant |
5.8% |
| Multiple Sclerosis |
5.0% |
| B Precursor Type Acute Leukaemia |
4.6% |
| Mantle Cell Lymphoma |
4.5% |
| Acute Promyelocytic Leukaemia |
4.3% |
| Prophylaxis |
4.1% |
| Constipation |
3.9% |
| Drug Use For Unknown Indication |
3.7% |
| Antifungal Prophylaxis |
2.8% |
| Pyrexia |
2.6% |
| Abdominal Pain |
2.5% |
| Nasopharyngitis |
2.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.7% |
| Hodgkin's Disease |
1.4% |
| Nausea |
1.4% |
| B-cell Small Lymphocytic Lymphoma |
1.2% |
|
| Febrile Neutropenia |
9.9% |
| White Blood Cell Count Decreased |
9.9% |
| Thrombocytopenia |
8.1% |
| Myelodysplastic Syndrome |
7.2% |
| Sepsis |
7.2% |
| Pyrexia |
6.3% |
| Staphylococcal Infection |
6.3% |
| Cardiomyopathy |
4.5% |
| Hepatitis B |
4.5% |
| Neutropenia |
4.5% |
| Bone Marrow Failure |
3.6% |
| Nausea |
3.6% |
| Pneumonia |
3.6% |
| Progressive Multifocal Leukoencephalopathy |
3.6% |
| Vomiting |
3.6% |
| Anal Ulcer |
2.7% |
| Cerebral Haemorrhage |
2.7% |
| Hypoxia |
2.7% |
| Lymphopenia |
2.7% |
| Multi-organ Failure |
2.7% |
|
| Concomitant |
| Prophylaxis |
17.6% |
| Neoplasm Malignant |
14.1% |
| Breast Cancer Metastatic |
10.0% |
| Breast Cancer |
7.4% |
| Acute Myeloid Leukaemia |
5.6% |
| Ovarian Cancer |
5.5% |
| Infection Prophylaxis |
5.0% |
| Bone Marrow Conditioning Regimen |
4.8% |
| Acute Monocytic Leukaemia |
3.6% |
| Acute Lymphocytic Leukaemia |
3.5% |
| Prophylaxis Against Graft Versus Host Disease |
3.5% |
| Product Used For Unknown Indication |
3.3% |
| Discomfort |
2.7% |
| Granulocyte Count Decreased |
2.7% |
| Hot Flush |
2.7% |
| Migraine |
2.7% |
| Diffuse Large B-cell Lymphoma |
1.8% |
| Antifungal Prophylaxis |
1.4% |
| Diffuse Large B-cell Lymphoma Stage Iv |
1.0% |
| Allergy Prophylaxis |
0.9% |
|
| Wound Treatment |
28.1% |
| Respiratory Failure |
10.5% |
| Thrombocytopenia |
7.0% |
| Drug Interaction |
5.3% |
| Herpes Zoster Disseminated |
5.3% |
| Hepatic Function Abnormal |
3.5% |
| Localised Infection |
3.5% |
| Mobility Decreased |
3.5% |
| Peripheral Sensory Neuropathy |
3.5% |
| Protein Total Decreased |
3.5% |
| Respiratory Tract Congestion |
3.5% |
| Tonsillar Hypertrophy |
3.5% |
| Vertigo |
3.5% |
| Vomiting |
3.5% |
| White Blood Cell Count Increased |
3.5% |
| Acute Febrile Neutrophilic Dermatosis |
1.8% |
| Acute Graft Versus Host Disease In Intestine |
1.8% |
| Acute Lymphocytic Leukaemia Recurrent |
1.8% |
| Acute Myeloid Leukaemia |
1.8% |
| Arthritis |
1.8% |
|
| Interacting |
| Acute Promyelocytic Leukaemia |
100.0% |
|
|
